Akebia TherapeuticsSTU:AX9 +8.59%51 Days Payable is 108.78 as of Mar. 2026, which is 12% above its 10-year median of 96.85. GuruFocus rates STU:AX9 with a GF Score™ of 51/100 and a GF Value™ of €1.12 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, Akebia Therapeutics ranks better than 59.57% on this metric.
The historical rank and industry rank for Akebia Therapeutics's Days Payable or its related term are showing as below:
STU:AX9'
s Days Payable Range Over the Past 10 Years
Min: 49.57 Med: 96.85 Max: 1169.85
Current: 105.66
During the past 13 years, Akebia Therapeutics's highest Days Payable was 1169.85. The lowest was 49.57. And the median was 96.85.
STU:AX9's Days Payable is ranked better than 59.57% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs STU:AX9: 105.66
Akebia Therapeutics's Days Payable
declined
from Mar. 2025 (169.52) to Mar. 2026 (108.78).
It may suggest that Akebia Therapeuticsaccelerated paying its suppliers.
Akebia Therapeutics Days Payable Related Terms
Akebia Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AX9 vs TKNO, ORGO, SIGA: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Akebia Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (STU:AX9) has a Days Payable of 108.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Akebia Therapeutics and its competitors. This is 12% above median its historical median of 96.85. Over the past decade, Akebia Therapeutics' Days Payable has ranged from 49.57 to 1,169.85. According to the industry distribution chart, Akebia Therapeutics ranks #372 out of 920 companies in the Drug Manufacturers industry, placing it in the top 40.4%.
Is Akebia Therapeutics' Days Payable too high?
Akebia Therapeutics' current Days Payable of 108.78 is 12% above median its 10-year median of 96.85. Over the past 10 years, this metric has ranged from a low of 49.57 to a high of 1,169.85. The Drug Manufacturers industry median Days Payable is 90.84. Akebia Therapeutics' value of 108.78 is 19.8% above this industry median. Based on the distribution chart, Akebia Therapeutics ranks #372 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Days Payable compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #372 out of 920 companies for Days Payable. This puts Akebia Therapeutics in the upper half of its industry. The industry median Days Payable is 90.84. Akebia Therapeutics' value of 108.78 is 19.8% above this benchmark. Historically, Akebia Therapeutics' own Days Payable has ranged from 49.57 to 1,169.85 over the past decade. While the company's 10-year median is 96.85 vs. the industry median of 90.84, Akebia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current Days Payable of 108.78 is 19.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current Days Payable is 108.78, which is 12% above median its own 10-year median of 96.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.12, compared to a current price of €0.98 — trading 12.6% below its estimated fair value. The current Days Payable is 108.78, which is 12% above median its 10-year median of 96.85 and 19.8% above the Drug Manufacturers industry median of 90.84. Akebia Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Days Payable is 108.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €0.98 is trading 12.6% below its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AX9:
Days Payable: 108.78 (12% above median its 10-year median of 96.85)
GF Value™: €1.12 vs. price of €0.98 (12.6% below fair value)
Industry Position: 19.8% above the Drug Manufacturers median (#372 of 920)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score
Get the complete analysis for STU:AX9
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
